Interrogation of brain miRNA and mRNA expression profiles reveals a molecular regulatory network that is perturbed by mutant huntingtin

Journal of Neurochemistry

Volumn 123, Issue 4, 2012, Pages 477-490

  Jin, Jing ^a   Cheng, Yong ^a   Zhang, Yongqing ^b   Wood, William ^b   Peng, Qi ^a   Hutchison, Emmette ^b   Mattson, Mark P ^a,b   Becker, Kevin G ^b   Duan, Wenzhen ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

gene array; Huntington's disease; miR 200; miRNA array; Trim2

Indexed keywords

HUNTINGTIN; MESSENGER RNA; MICRORNA 200A; MICRORNA 200C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOINFORMATICS; BRAIN CORTEX; CELL SURVIVAL; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE COURSE; ENZYME ACTIVITY; GENE EXPRESSION PROFILING; GENE TARGETING; GENETIC REGULATION; HUNTINGTON CHOREA; MALE; MOUSE; NERVE CELL; NERVE CELL DIFFERENTIATION; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RNA ANALYSIS; SYNAPSE;

AGE FACTORS; ANIMALS; BRAIN; COMPUTATIONAL BIOLOGY; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; GREEN FLUORESCENT PROTEINS; HUMANS; HUNTINGTON DISEASE; MICE; MICE, TRANSGENIC; MICRORNAS; NERVE TISSUE PROTEINS; NEURONS; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEPTIDES; RNA, MESSENGER;

MUS;

EID: 84867582241     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2012.07925.x     Document Type: Article

References (62)

1. Augood S. J., Faull R. L., and, Emson P. C., (1997a) Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann. Neurol. 42, 215-221.
2. Augood S. J., Westmore K., and, Emson P. C., (1997b) Phenotypic characterization of neurotensin messenger RNA-expressing cells in the neuroleptic-treated rat striatum: a detailed cellular co-expression study. Neuroscience 76, 763-774.
3. Bak M., Silahtaroglu A., Moller M., Christensen M., Rath M. F., Skryabin B., Tommerup N., and, Kauppinen S., (2008) MicroRNA expression in the adult mouse central nervous system. RNA 14, 432-444.
4. Balastik M., Ferraguti F., Pires-da Silva A., Lee T. H., Alvarez-Bolado G., Lu K. P., and, Gruss P., (2008) Deficiency in ubiquitin ligase TRIM2 causes accumulation of neurofilament light chain and neurodegeneration. Proc. Natl Acad. Sci. USA 105, 12016-12021.
5. Barton W. A., Liu B. P., Tzvetkova D., Jeffrey P. D., Fournier A. E., Sah D., Cate R., Strittmatter S. M., and, Nikolov D. B., (2003) Structure and axon outgrowth inhibitor binding of the Nogo-66 receptor and related proteins. EMBO J. 22, 3291-3302.
6. Bilen J., Liu N., and, Bonini N. M., (2006) A new role for microRNA pathways: modulation of degeneration induced by pathogenic human disease proteins. Cell Cycle 5, 2835-2838.
7. Butz S., Okamoto M., and, Sudhof T. C., (1998) A tripartite protein complex with the potential to couple synaptic vesicle exocytosis to cell adhesion in brain. Cell 94, 773-782.
8. Cattaneo E., Zuccato C., and, Tartari M., (2005) Normal huntingtin function: an alternative approach to Huntington's disease. Nat. Rev. Neurosci. 6, 919-930.
9. Chamberlain L. H., Graham M. E., Kane S., Jackson J. L., Maier V. H., Burgoyne R. D., and, Gould G. W., (2001) The synaptic vesicle protein, cysteine-string protein, is associated with the plasma membrane in 3T3-L1 adipocytes and interacts with syntaxin 4. J. Cell Sci. 114, 445-455.
10. Cheng Y., Peng Q., Hou Z., Aggarwal M., Zhang J., Mori S., Ross C. A., and, Duan W., (2011) Structural MRI detects progressive regional brain atrophy and neuroprotective effects in N171-82Q Huntington's disease mouse model. Neuroimage 56, 1027-1034.
11. Choi P. S., Zakhary L., Choi W. Y., et al,. (2008) Members of the miRNA-200 family regulate olfactory neurogenesis. Neuron 57, 41-55.
12. Chung C. Y., Koprich J. B., Siddiqi H., and, Isacson O., (2009) Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J. Neurosci. 29, 3365-3373.
13. Conrad R., Barrier M., and, Ford L. P., (2006) Role of miRNA and miRNA processing factors in development and disease. Birth Defects Res. C Embryo Today 78, 107-117.
14. Crook Z. R., and, Housman D. E., (2012) Dysregulation of dopamine receptor D2 as a sensitive measure for Huntington disease pathology in model mice. Proc. Natl Acad. Sci. USA 109, 7487-7492.
15. Cuellar T. L., Davis T. H., Nelson P. T., Loeb G. B., Harfe B. D., Ullian E., and, McManus M. T., (2008) Dicer loss in striatal neurons produces behavioral and neuroanatomical phenotypes in the absence of neurodegeneration. Proc. Natl Acad. Sci. USA 105, 5614-5619.
16. Cunningham J. M., Oberg A. L., Borralho P. M., et al,. (2009) Evaluation of a new high-dimensional miRNA profiling platform. BMC Med. Genomics 2, 57.
17. Dodson P. D., Barker M. C., and, Forsythe I. D., (2002) Two heteromeric Kv1 potassium channels differentially regulate action potential firing. J. Neurosci. 22, 6953-6961.
18. Dodson P. D., Billups B., Rusznak Z., Szucs G., Barker M. C., and, Forsythe I. D., (2003) Presynaptic rat Kv1.2 channels suppress synaptic terminal hyperexcitability following action potential invasion. J. Physiol. 550, 27-33.
19. Duan W., Guo Z., Jiang H., Ware M., and, Mattson M. P., (2003) Reversal of behavioral and metabolic abnormalities, and insulin resistance syndrome, by dietary restriction in mice deficient in brain-derived neurotrophic factor. Endocrinology 144, 2446-2453.
20. Duan W., Peng Q., Masudaa N., Ford E., Tryggestad E., Ladenheim B., Zhao M., cadet J. L., Wong J., and, Ross C. A., (2008) Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease. Neurobiol. Dis. 30, 312-322.
21. Etherton M. R., Blaiss C. A., Powell C. M., and, Sudhof T. C., (2009) Mouse neurexin-1alpha deletion causes correlated electrophysiological and behavioral changes consistent with cognitive impairments. Proc. Natl Acad. Sci. USA 106, 17998-18003.
22. Fairless R., Masius H., Rohlmann A., Heupel K., Ahmad M., Reissner C., Dresbach T., and, Missler M., (2008) Polarized targeting of neurexins to synapses is regulated by their C-terminal sequences. J. Neurosci. 28, 12969-12981.
23. Ferrante R. J., Gutekunst C. A., Persichetti F., McNeil S. M., Kowall N. W., Gusella J. F., MacDonald M. E., Beal M. F., and, Hersch S. M., (1997) Heterogeneous topographic and cellular distribution of huntingtin expression in the normal human neostriatum. J. Neurosci. 17, 3052-3063.
24. Fusco F. R., Chen Q., Lamoreaux W. J. II, Figueredo-Cardenas G., Jiao Y., Coffman J. A., Surmeier D. J., Honig M. G., Carlock L. R., and, Reiner A., (1999) Cellular localization of huntingtin in striatal and cortical neurons in rats: lack of correlation with neuronal vulnerability in Huntington's disease. J. Neurosci. 19, 1189-1202.
25. Goold R., Hubank M., Hunt A., Holton J., Menon R. P., Revesz T., Pandolfo M., and, Matilla-Duenas A., (2007) Down-regulation of the dopamine receptor D2 in mice lacking ataxin 1. Hum. Mol. Genet. 16, 2122-2134.
26. Gray S. G., (2011) Targeting Huntington's disease through histone deacetylases. Clin. Epigenetics 2, 257-277.
27. Grimson A., Farh K. K., Johnston W. K., Garrett-Engele P., Lim L. P., and, Bartel D. P., (2007) MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol. Cell 27, 91-105.
28. Guillerme-Bosselut F., Forestier L., Jayat-Vignoles C., Vilotte J., Popa I., Portoukalian J., Le Dur A., Laude H., Julien R., and, Gallet P. F., (2009) Glycosylation-related gene expression profiling in the brain and spleen of scrapie-affected mouse. Glycobiology 19, 879-889.
29. Hodges A., Strand A. D., Aragaki A. K., et al,. (2006) Regional and cellular gene expression changes in human Huntington's disease brain. Hum. Mol. Genet. 15, 965-977.
30. Johnson R., Zuccato C., Belyaev N. D., Guest D. J., Cattaneo E., and, Buckley N. J., (2008) A microRNA-based gene dysregulation pathway in Huntington's disease. Neurobiol. Dis. 29, 438-445.
31. Khazaei M. R., Bunk E. C., Hillje A. L., Jahn H. M., Riegler E. M., Knoblich J. A., Young P., and, Schwamborn J. C., (2011) The E3-ubiquitin ligase TRIM2 regulates neuronal polarization. J. Neurochem. 117, 29-37.
32. Kim J., Inoue K., Ishii J., Vanti W. B., Voronov S. V., Murchison E., Hannon G., and, Abeliovich A., (2007) A MicroRNA feedback circuit in midbrain dopamine neurons. Science 317, 1220-1224.
33. Kosik K. S., (2006) The neuronal microRNA system. Nat. Rev. Neurosci. 7, 911-920.
34. Krek A., Grun D., Poy M. N., et al,. (2005) Combinatorial microRNA target predictions. Nat. Genet. 37, 495-500.
35. Lam Y. C., Bowman A. B., Jafar-Nejad P., et al,. (2006) ATAXIN-1 interacts with the repressor Capicua in its native complex to cause SCA1 neuropathology. Cell 127, 1335-1347.
36. Lau P., and, de Strooper B., (2010) Dysregulated microRNAs in neurodegenerative disorders. Semin. Cell Dev. Biol. 21, 768-773.
37. Lee S. T., Chu K., Im W. S., et al,. (2011) Altered microRNA regulation in Huntington's disease models. Exp. Neurol. 227, 172-179.
38. Leone S., Mutti C., Kazantsev A., Sturlese M., Moro S., Cattaneo E., Rigamonti D., and, Contini A., (2008) SAR and QSAR study on 2-aminothiazole derivatives, modulators of transcriptional repression in Huntington's disease. Bioorg. Med. Chem. 16, 5695-5703.
39. Lintas C., Sacco R., Garbett K., et al. (2009) Involvement of the PRKCB1 gene in autistic disorder: significant genetic association and reduced neocortical gene expression. Mol. Psychiatry 14, 705-718.
40. Luthi-Carter R., Strand A., Peters N. L., et al,. (2000) Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum. Mol. Genet. 9, 1259-1271.
41. Luthi-Carter R., Strand A. D., Hanson S. A., et al,. (2002) Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects. Hum. Mol. Genet. 11, 1927-1937.
42. Mason S., Piper M., Gronostajski R. M., and, Richards L. J., (2009) Nuclear factor one transcription factors in CNS development. Mol. Neurobiol. 39, 10-23.
43. Meng X., Kanwar N., Du Q., Goping I. S., Bleackley R. C., and, Wilkins J. A., (2009) PPP1R9B (Neurabin 2): involvement and dynamics in the NK immunological synapse. Eur. J. Immunol. 39, 552-560.
44. Miller L. C., Swayne L. A., Chen L., Feng Z. P., Wacker J. L., Muchowski P. J., Zamponi G. W., and, Braun J. E., (2003) Cysteine string protein (CSP) inhibition of N-type calcium channels is blocked by mutant huntingtin. J. Biol. Chem. 278, 53072-53081.
45. Nakaya N., Lee H. S., Takada Y., Tzchori I., and, Tomarev S. I., (2008) Zebrafish olfactomedin 1 regulates retinal axon elongation in vivo and is a modulator of Wnt signaling pathway. J. Neurosci. 28, 7900-7910.
46. Packer A. N., Xing Y., Harper S. Q., Jones L., and, Davidson B. L., (2008) The bifunctional microRNA miR-9/miR-9* regulates REST and CoREST and is downregulated in Huntington's disease. J. Neurosci. 28, 14341-14346.
47. Pahnke J., Mix E., Knoblich R., et al,. (2004) Overexpression of glial cell line-derived neurotrophic factor induces genes regulating migration and differentiation of neuronal progenitor cells. Exp. Cell Res. 297, 484-494.
48. Pulido R., Krueger N. X., Serra-Pages C., Saito H., and, Streuli M., (1995a) Molecular characterization of the human transmembrane protein-tyrosine phosphatase delta. Evidence for tissue-specific expression of alternative human transmembrane protein-tyrosine phosphatase delta isoforms. J. Biol. Chem. 270, 6722-6728.
49. Pulido R., Serra-Pages C., Tang M., and, Streuli M., (1995b) The LAR/PTP delta/PTP sigma subfamily of transmembrane protein-tyrosine-phosphatases: multiple human LAR, PTP delta, and PTP sigma isoforms are expressed in a tissue-specific manner and associate with the LAR-interacting protein LIP.1. Proc. Natl Acad. Sci. USA 92, 11686-11690.
50. Rodrigues N. R., Theodosiou A. M., Nesbit M. A., Campbell L., Tandle A. T., Saranath D., and, Davies K. E., (2000) Characterization of Ngef, a novel member of the Dbl family of genes expressed predominantly in the caudate nucleus. Genomics 65, 53-61.
51. Runne H., Régulier E., Kuhn A., Zala D., Gokce O., Perrin V., Sick B., Aebischer P., Déglon N., and, Luthi-Carter R., (2008) Dysregulation of gene expression in primary neuron models of Huntington's disease shows that polyglutamine-related effects on the striatal transcriptome may not be dependent on brain circuitry. J. Neurosci. 28, 9723-9731.
52. Sinha M., Ghose J., Das E., and, Bhattarcharyya N. P., (2011) Altered microRNAs in STHdh(Q111)/Hdh(Q111) cells: miR-146a targets TBP. Biochem. Biophys. Res. Commun. 396, 742-747.
53. Sudo K., Ito H., Iwamoto I., Morishita R., Asano T., and, Nagata K., (2006) Identification of a cell polarity-related protein, Lin-7B, as a binding partner for a Rho effector, Rhotekin, and their possible interaction in neurons. Neurosci. Res. 56, 347-355.
54. Tang X., Guilherme A., Chakladar A., Powelka A. M., Konda S., Virbasius J. V., Nicoloro S. M., Straubhaar J., and, Czech M. P., (2006) An RNA interference-based screen identifies MAP4K4/NIK as a negative regulator of PPARgamma, adipogenesis, and insulin-responsive hexose transport. Proc. Natl Acad. Sci. USA 103, 2087-2092.
55. Thomson J. M., Parker J., Perou C. M., and, Hammond S. M., (2004) A custom microarray platform for analysis of microRNA gene expression. Nat. Methods 1, 47-53.
56. Trettel F., Rigamonti D., Hilditch-Maguire P., Wheeler V. C., Sharp A. H., Persichetti F., Cattaneo E., and, MacDonald M. E., (2000) Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum. Mol. Genet. 9, 2799-2809.
57. Trivedi S., and, Ramakrishna G., (2009) miRNA and neurons. Int. J. Neurosci. 119, 1995-2016.
58. Trottier Y., Lutz Y., Stevanin G., Imbert G., Devys D., Cancel G., Saudou F., Weber C., David G., and, Tora L., (1995) Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. Nature 378, 403-406.
59. Wallace M. J., Fladd C., Batt J., and, Rotin D., (1998) The second catalytic domain of protein tyrosine phosphatase delta (PTP delta) binds to and inhibits the first catalytic domain of PTP sigma. Mol. Cell. Biol. 18, 2608-2616.
60. Wang K. C., Koprivica V., Kim J. A., Sivasankaran R., Guo Y., Neve R. L., and, He Z., (2002) Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth. Nature 417, 941-944.
61. Yu Z. X., Li S. H., Evans J., Pillarisetti A., Li H., and, Li X. J., (2003) Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease. J. Neurosci. 23, 2193-2202.
62. Zuccato C., Valenza M., and, Cattaneo E., (2010) Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol. Rev. 90, 905-981.